ABS shares lifted by 35% revenue growth, clinical progress outlook
ABS cited 35% revenue growth and positive clinical progress, despite supply risks, driving a strong outlook.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.